Pomalyst and Rheumatoid arthritis - a phase IV clinical study of FDA data

Summary:

Rheumatoid arthritis is reported as a side effect among people who take Pomalyst (pomalidomide), especially for people who are female, 60+ old, also take Eliquis, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Rheumatoid arthritis when taking Pomalyst. It is created by eHealthMe based on reports of 80,394 people who have side effects when taking Pomalyst from the FDA, and is updated regularly.

What is Pomalyst?

Pomalyst has active ingredients of pomalidomide. eHealthMe is studying from 80,400 Pomalyst users. Check the latest studies of Pomalyst.

What is Rheumatoid arthritis?

Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints) is found to be associated with 1,679 drugs and 2,122 conditions by eHealthMe. Check the latest studies of Rheumatoid arthritis.

On Jul, 18, 2026

80,394 people reported to have side effects when taking Pomalyst.
Among them, 12 people (0.01%) have Rheumatoid arthritis.

Could Pomalyst cause Rheumatoid arthritis?

Among these 12 people:

What is the gender of people who have Rheumatoid arthritis when taking Pomalyst? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Rheumatoid arthritis when taking Pomalyst? *

What are other drugs people take besides Pomalyst? *

What are other side effects people have besides Rheumatoid arthritis? *

Fatigue (feeling of tiredness): 3 people, 25.00%
Weakness: 1 person, 8.33%
Upper Limb Fracture: 1 person, 8.33%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 8.33%
Arthropathy: 1 person, 8.33%
Cough: 1 person, 8.33%
Diarrhea: 1 person, 8.33%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 8.33%
Intervertebral Disc Protrusion (spinal disc protrusion): 1 person, 8.33%
Nausea (feeling of having an urge to vomit): 1 person, 8.33%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 11 people, 91.67%
Amyloidosis (a tumour within which amyloid is produced): 2 people, 16.67%
Cancer Pain: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Pomalyst and have Rheumatoid arthritis?

- Check whether Rheumatoid arthritis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pomalyst:

Pomalyst (80,400 reports)

Browse all side effects of Pomalyst:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rheumatoid arthritis:

Rheumatoid arthritis (1,679 drugs)

Browse all the conditions that are associated with Rheumatoid arthritis:

Rheumatoid arthritis (2,122 conditions)

Related publications that referenced our studies

Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Ahmed AB, Radwan AM, Baddary HM, "Prevalence of Generalized Anxiety Disorder in Patients with Rheumatoid Arthritis and its Relationship with Disease Activity", The Egyptian Journal of Hospital Medicine, 2016 Jan .
Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Ahmed AB, Radwan AM, Baddary HM, "Prevalence of Generalized Anxiety Disorder in Patients with Rheumatoid Arthritis and its Relationship with Disease Activity", The Egyptian Journal of Hospital Medicine, 2016 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pomalidomide (the active ingredients of Pomalyst) and Pomalyst (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.